The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TAS-116, an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: An open-label, dose-finding, and expansion phase Ib trial (EPOC1704).
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Sysmex
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; Otsuka; PRA health science; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Daisuke Kotani
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Takeda
Consulting or Advisory Role - Merck Serono
 
Yasutoshi Kuboki
Honoraria - Bayer; Lilly Japan; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; MSD Oncology; Novartis; Ono Pharmaceutical; Sysmex; Takeda
 
Kenichi Harano
Honoraria - AstraZeneca; Chugai Pharma; Eisai; MSD K.K; Taiho Pharmaceutical
Consulting or Advisory Role - Takeda
 
Yoichi Naito
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; Lilly; Meiji Seika Kaisha; Novartis; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan; Lilly; Merck Serono; Nippon Kayaku; Pfizer; Roche
 
Mitsuko Suzuki
No Relationships to Disclose
 
Miki Fukutani
No Relationships to Disclose
 
Hikari Shima
No Relationships to Disclose
 
Tsukiko Higuchi
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma; Johnson & Johnson
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - AstraZeneca; Chugai Pharma; Pfizer; Taiho Pharmaceutical
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices; Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Astellas Pharma; AstraZeneca; Becton Dickinson; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Debiopharm Group; KYOWA HAKKO BIO; Kyowa Hakko Kirin; Merck Serono; Oncolys BioPharma; Ono Pharmaceutical; Pfizer; SRL Diagnostics; Sumitomo Group; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)